A Study to Evaluate the Potential Drug-Drug Interaction Between Darunavir and Danoprevir When Administered Together With Low-Dose Ritonavir in Healthy Volunteers

Hoffmann-La Roche0 sites40 target enrollmentFebruary 2012

ConditionsHealthy Volunteer

Interventionsritonavir darunavir danoprevir

Drugsdanoprevir darunavir ritonavir

Overview

Phase: Phase 1
Intervention: ritonavir
Conditions: Healthy Volunteer
Sponsor: Hoffmann-La Roche
Enrollment: 40
Primary Endpoint: Effect of coadministration of darunavir (DRV), danoprevir (DNV) and ritonavir (RTV) on DRV/DNV/RTV pharmacokinetics: Area under the concentration-time curve (AUC)
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

This randomized, open-label, multiple-dose, 2-period crossover study will evaluate potential drug-drug interactions between darunavir and danoprevir when administered together with low-dose ritonavir in healthy volunteers. In Period 1, subjects will be randomized to receive either darunavir or danoprevir together with low-dose ritonavir for 10 days. In Period 2, all subjects will receive darunavir plus danoprevir together with ritonavir for 10 days. Anticipated time on study treatment is 20 days.

Registry

clinicaltrials.gov

Start Date

February 2012

End Date

March 2012

Last Updated

9 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

Hoffmann-La Roche

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Healthy non-smoking male and female adults, 18 - 55 years of age, inclusive
•Healthy status defined by absence of evidence of any active or chronic disease
•Medical history without major, recent, or ongoing pathology
•Weight \>/= 55 kg
•Body mass index (BMI) 18.0 - 32.0 kg/m2
•Ability and willingness to abstain from alcohol, xanthine-containing beverages or food (coffee, tea, cola, chocolate, "energy drinks") from 72 hours prior to entry in the clinical site center until discharge
•Females of child-bearing potential and males and their female partners of child-bearing potential must agree to use 2 forms of contraception, one of which must be a barrier method, during the study and for 90 days after the last drug administration. Acceptable barrier forms of contraception are condom and diaphragm; acceptable non-barrier forms of contraception for this study are non-hormonal intrauterine device (IUD) and/or spermicide

Exclusion Criteria

•Pregnant or lactating females or males with female partners who are pregnant or lactating
•Any history of clinically significant cardiovascular or cerebrovascular disease, hypertension, and/or infections
•Positive test for drugs of abuse at screening or prior to admission to the clinical site during any study period
•Positive for hepatitis B, hepatitis C or HIV infection
•Current smokers or subjects who have discontinued smoking less than 6 months prior to first dose of study medication
•Use of hormonal contraceptives within 30 days before the first dose of study medication
•History of clinically significant drug-related allergy (such as anaphylaxis) or hepatotoxicity

Arms & Interventions

A danoprevir

Intervention: ritonavir

B darunavir

Intervention: darunavir

B darunavir

Intervention: ritonavir

C danoprevir/darunavir

Intervention: danoprevir

C danoprevir/darunavir

Intervention: darunavir

A danoprevir

Intervention: danoprevir

C danoprevir/darunavir

Intervention: ritonavir

Outcomes

Primary Outcomes

Effect of coadministration of darunavir (DRV), danoprevir (DNV) and ritonavir (RTV) on DRV/DNV/RTV pharmacokinetics: Area under the concentration-time curve (AUC)

Time Frame: approximately 2 months